MedTrace Logo

Investigating Neurocognitive, Motor and Biological Effects of MindLenses Professional in Neurological Diseases

NCT05826626 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-10-15

No results posted yet for this study

Summary

This study aims to explore the effects of the treatment with MindLenses Professional device on cognitive and motor performances,as well as on the levels of a neurotrophic factor implied in brain plasticity, that is the brain derived neurotrophic factor (BDNF), in neurological patients. A further aim of the study is to evaluate if the treatment's efficacy could depend on specific characteristics of brain alteration (lesion vs atrophy). The treatment combines prismatic adaptation with serious games for cognitive training, for a total of 10 sessions. 30 patients with stroke and 30 patients with Mild Cognitive Impairment will be enrolled.

Conditions

Interventions

DEVICE

MindLenses Professional

MindLenses professional's device combines the prismatic adaptation (PA) procedure with the administration of serious games (SG) for cognitive training using a tablet

BEHAVIORAL

Conventional rehabilitation

Conventional rehabilition consists in computerized exercises focused on the main cognitive domains

Sponsors & Collaborators

  • Restorative Neurotechnologies S.r.l.

    collaborator UNKNOWN

  • IRCCS San Camillo, Venezia, Italy

    lead OTHER

Principal Investigators

  • Francesca Burgio, PhD · IRCCS San Camillo Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-05
Primary Completion
2024-04-30
Completion
2024-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05826626 on ClinicalTrials.gov